Connect with us
https://yoursportsnation.com/wp-content/uploads/2025/07/call-to-1.png

Technology

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market Initial production has commenced with six flavor options Expanded pre-launch consumer testing planned for Q2 2025 Aspire to launch BUZZ BOMB™ at two major upcoming fitness conventions Marketing plan focused on cost-effective multi-channel digital strategy targeting […]

Published

2 months ago

on


  • Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market

  • Initial production has commenced with six flavor options

  • Expanded pre-launch consumer testing planned for Q2 2025

  • Aspire to launch BUZZ BOMB™ at two major upcoming fitness conventions

  • Marketing plan focused on cost-effective multi-channel digital strategy targeting primary influencers, direct response sales and traditional retail sales channels

  • Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030

HUMACO, PUERTO RICO and NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced the brand name BUZZ BOMB™ and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB™ features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential.

Aspire has commenced initial production of BUZZ BOMB™, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology.The pre-workout formula is conveniently packaged in a single serving packet for easy on-the-go use. Consumers will have a choice of six BUZZ BOMB™ flavors, including Tropical Fruit, Mixed Berry, Watermelon, Lemon Lime, Peach Mango, and Mocha Coffee.

Fitness Convention Booth and Sponsor Events for BUZZ BOMB™ Launch

The Company expects to begin expanded pre-launch consumer testing of this supplement product during the second quarter of 2025. In August, the Company will have a booth and be an event sponsor at two of the largest fitness conferences in the nation where over 50,000 people interested in health, fitness, optimization, nutrition, and overall wellbeing will be able to taste, sample, and experience the BUZZ BOMB™ pre-workout supplement.

FITCON Expo
https://fitcon.com/

August 1-2, 2025
Mountain America Expo Center, Salt Lake City, Utah

The Fit Expo™
https://thefitexpo.com/cities/anaheim/
August 2-3
The Anaheim Convention Center, Anaheim, CA

Management Commentary

“The introduction of Aspire’s caffeine-based “Buzz Bomb™” Sublingual Pre-Workout energy supplement has the ideal unique characteristics to disrupt the fast-growing, multi-billion-dollar Sports Nutrition and Fitness market,” said Kraig Higginson, Chief Executive Officer of Aspire. “We are excited about the early feedback from fitness trainers and athletes-who love how clean and simple our product is–and we look forward to the implementation of our phased marketing plan as we prepare for our market launch in the early third quarter. Initial production, performed by Desert Stream, a leading private label manufacturer in the health and wellness industry, has proceeded as planned and we expect to have ample product available for consumer testing and launch.

While we are initially focused on the fitness pre-workout market, we believe the product also has tremendous broad market appeal in the Cognitive Focus and Energy Boost markets for professionals seeking a safe, healthy way to meet energy demands at work. We believe it may also appeal to a growing Health and Nutrition market as a weight loss enhancement, and as a coffee alternative, providing the taste, energy, and cognitive boost of coffee, while on the go, without the adverse effects of disrupting the gut micro biome and the liver, that is associated with long term coffee consumption.”

Higginson added, “As part of our commercial and revenue strategy, BUZZ BOMB™, is expected to provide Aspire with the opportunity for rapid, cost-effective market entry, and early revenue and cash flow while we complete our FDA clinical trials and application process for our high-dose aspirin product.”

BUZZ BOMB™: Disruptive Characteristics

The Pre-Workout supplement market segment is flooded with many options for energy boosting and hydration products. Many, if not most, of these products today are based on a powdered “mix + water” combination that take 20-30 minutes to digest and begin to provide performance benefits. This disadvantage complicates use, response management, caffeine control, and effectiveness. In contrast, Buzz Bomb™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.

Market research shows that immediacy, ease of use and time management (take as needed, when needed) ranks highest in consumer preferences. Buzz Bomb™ offers potentially disruptive benefits and product characteristics that is expected to drive market penetration with significant differentiation, leading to rapid customer conversion, acquisition, and brand identity in this market.

Aspire’s sublingual nano technology is designed to deliver caffeine directly to the blood stream, bringing its unique disruptive benefits to the Pre-Workout market. These unique benefits provide significant product differentiation from powder mix beverage products that currently dominate the market segment.

BUZZ BOMB™ Disruptive Features:

  • Speed – works nearly immediately vs. 20-30 minutes

  • Convenience – easy to use small packets vs. mix beverages

  • Energy management – use as needed, when needed to manage energy

  • Single Safe Ingredients – well known benefits and use of caffeine

  • Low manufacturing & packaging costs – competitive pricing with high margin potential

  • Easy powerful product demonstration – enabling low-cost sample kits

Pre-workout Supplements Market & Growth Drivers

According to Research and Market Reports recent report, “The global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030.”

Growth Drivers

  • Rising fitness culture and gym memberships

  • Consumer focus on performance and recovery

  • Expanding demographics (women, Gen Z, casual exercisers)

  • Growth of RTD (“Ready To Drink”- no mixing) formats & natural formulations

  • Digital fitness and influencer-led marketing

About the Aspire Targeted Oral Delivery Platform

Aspire’s technology delivers a soluble, fast acting granular or powder formulation which has been developed by using our patent-pending methodology, and “trade secret” process. The technology’s new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of supplements and other substances. The benefits of “rapid absorption” are to provide rapid impact in more precise quantities.

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire



Link

8
Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Revelyst To Acquire GolfLogix | citybiz

GolfLogix joins Foresight Sports, Bushnell Golf and PinSeeker in Revelyst’s Golf Technology platform, a leading portfolio of golf technology brands GolfLogix joins Foresight Sports, Bushnell Golf and PinSeeker in Revelyst’s Golf Technology platform, a leading portfolio of golf technology brands The addition of GolfLogix boosts course-mapping capabilities across Revelyst, especially for the Bushnell Golf app […]

Published

41 minutes ago

on

July 16, 2025

By


GolfLogix joins Foresight Sports, Bushnell Golf and PinSeeker in Revelyst’s Golf Technology platform, a leading portfolio of golf technology brands

  • GolfLogix joins Foresight Sports, Bushnell Golf and PinSeeker in Revelyst’s Golf Technology platform, a leading portfolio of golf technology brands
  • The addition of GolfLogix boosts course-mapping capabilities across Revelyst, especially for the Bushnell Golf app
  • This acquisition further expands the company’s product ecosystem, instantly increasing its on-course presence while strengthening its off-course and in-simulator offerings

SAN DIEGO–(BUSINESS WIRE)–Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies, today announced the acquisition of GolfLogix, a leading golf course mapping company featuring the most expansive, detailed library of more than 40,000 courses worldwide, from 8AM Golf. The acquisition closed on July 9. Terms were not disclosed.

Founded in 1999, GolfLogix was the first company to introduce handheld GPS to the golf industry and has continued to innovate including releasing the first Golf GPS app in 2009, a revolutionary Puttbreaks feature in 2018 and now, the first 3D virtual reality offering in a Golf GPS app.

The GolfLogix business will be integrated into Revelyst’s Golf Technology platform, which recently announced a rebranding. The addition of GolfLogix gives Revelyst’s San Diego-based platform another innovative brand in its growing portfolio, which includes Foresight Sports, Bushnell Golf and PinSeeker. This acquisition further expands the company’s product ecosystem, instantly increasing its software capabilities and on-course presence.

“We’re incredibly excited about this acquisition of GolfLogix,” said Eric Nyman, CEO of Revelyst. “This addition of a well-respected golf technology innovator strengthens our leadership in the golf tech space and opens the door to new categories where we see tremendous opportunity. By bringing GolfLogix onto Team Revelyst, we can accelerate our growth strategy and, more importantly, ensure that golfers of all levels have a one-stop shop for improving their game.”

Based in Scottsdale, Ariz., GolfLogix has been professionally mapping courses for nearly 25 years and owns the largest, most up-to-date golf course database in the world. Today, the company has a library of more than 40,000 golf courses mapped across the globe for use in the GolfLogix app, including its new, first of its kind 3D mapping features released in April 2025, its GreenBooks offering and through licensing. GolfLogix will maintain a presence in Scottsdale, which will become a digital studio for Revelyst Golf Technology in the future.

“This is a game-changing addition to our portfolio,” said Jeff Foster, GM and President of Revelyst Golf Technology. “It not only boosts our market presence but also gives us the tools to innovate in areas we’ve been eager to explore. We’re confident this will bring significant value to our customers and app users and fuel our next phase of growth.”

GolfLogix’s cofounders Scott Lambrecht and Pete Charleston said teaming up with Revelyst made the most sense as they look to begin the next chapter of their company. The new home will enable GolfLogix to double down on tech investment and reach scores of golf fans seeking to enhance their golf game through the world’s most innovative on- and off-course technology. Lambrecht and Charleston will remain with Revelyst post-acquisition.

“Joining forces with a leading golf tech company is an incredible opportunity for our team and our brand,” said Lambrecht, GolfLogix CEO. “We’re thrilled to bring our expertise into a larger ecosystem where we can reach more golfers and push innovation even further.”

Added Charleston, GolfLogix president: “This partnership allows us to scale in ways we couldn’t on our own. We’re excited to be part of a company that shares our passion for the game and is committed to delivering cutting-edge solutions for golfers everywhere.”

Reed Smith LLP served as legal adviser to Revelyst in connection with the transaction.

About GolfLogix

As the most frequently used app for golf, over 7 million golfers have downloaded GolfLogix on the world’s top-selling smartphones. GolfLogix has also created enhanced Green Books for over 15,000 courses worldwide. Dedicated to offering consumers the most advanced green mapping and GPS solutions with the most useful features at accessible prices, GolfLogix helps improve individual performance.

About Revelyst

Revelyst Inc. is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.



Link

0
Continue Reading

Technology

The FDA Says Whoop’s Blood Pressure Feature Is Illegal, but It’s Still Active (for Now)

We may earn a commission from links on this page. When Whoop introduced its new hardware and membership tiers back in May, one of the devices was called the MG, with the abbreviation standing for “Medical Grade.” Among the big features ostensibly making it worth the upgrade was something called Blood Pressure Insights. But now […]

Published

43 minutes ago

on

July 16, 2025

By


We may earn a commission from links on this page.

When Whoop introduced its new hardware and membership tiers back in May, one of the devices was called the MG, with the abbreviation standing for “Medical Grade.” Among the big features ostensibly making it worth the upgrade was something called Blood Pressure Insights. But now the FDA has sent Whoop a warning letter saying that Whoop is marketing an unapproved medical device.

Whoop is a screenless fitness tracker with an extensive array of features that track a user’s fitness, sleep, and other metrics related to wellness. (You can read about my experiences tracking my health with Whoop here.)

In a message to members posted today on the r/Whoop subreddit, Whoop stated that, despite the FDA letter, the Blood Pressure Insights feature “remains available” to members on the Life tier. This is the highest tier of membership and the only one that was marketed as including Blood Pressure Insights. Whoop also stated that any regulatory issues with the FDA don’t affect devices sold outside the U.S.

If you have a Whoop 4.0 or 5.0, this doesn’t apply to you either; the issue is solely about the blood pressure feature offered in the top-tier Life membership ($359/year) with the MG (“medical grade”) device. 

Why the FDA intervened (and how Whoop responded)

According to the FDA’s letter, measuring and reporting users’ blood pressure classifies the Blood Pressure Insights feature as a medical device. Medical devices that can measure blood pressure need to be approved by the FDA before they go to market. 

Note that the FDA’s letter is directed at the Blood Pressure Insights feature, not the Whoop MG hardware itself. Whoop argued (to the FDA, according to the letter) that the blood pressure feature falls under the definition of software that is intended for “maintaining or encouraging a healthy lifestyle,” and thus is exempt from the rules for medical devices. 

The FDA counters that the measurement of blood pressure is “inherently associated with the diagnosis of hypo- and hypertension, and is therefore intended for use in the diagnosis of a disease or other condition, or in the cure, mitigation, treatment, or prevention of disease.” The FDA notes that they have approved other blood pressure monitors that didn’t make direct claims about disease, and they consider Whoop’s blood pressure readings to be no different.

Whoop sees it differently, saying to members: “Wellness features like this are common in wearable technology without requiring FDA review, like tracking your respiratory rate or HRV, and provide valuable insights to support you in making better decisions. Blood pressure is no different.”

You can read the FDA’s entire warning letter here. It asks Whoop to reply with an explanation of how they will follow the rules going forward. You can also read Whoop’s notice to members here, where they explain why they believe they are not violating the law, and state that the Blood Pressure Insights feature remains available. 


What do you think so far?

What this could mean for Whoop

To be fair, Whoop was perhaps sticking its neck out a bit by offering an MG (“medical grade”) edition of its wristband. The standard model, without the blood pressure feature, is the Whoop 5.0, which provides the company’s established fitness and wellness metrics for either $199/year (the “One” membership) or $239/year (the “Peak” membership). But the Whoop MG is an upgraded version that goes with the “Life” membership for $359/year. 

What does that significant price hike buy you? Three features, according to Whoop’s pricing page, and two of those are “medically regulated,” in Whoop’s words: ECG readings and irregular heart rhythm notifications. Both of these can tell you if there are problems with the rhythm of your heartbeat. According to Whoop’s country-by-country availability page, ECG readings are available in 39 countries, including the U.S. This feature requires you to put your fingers on the device’s metal clasp and leave them there while it takes a reading.

Irregular heart rhythm notifications, meanwhile, are available in 36 countries, but the U.S. is not one of them.

Blood pressure is the third feature (or, if you’re in the U.S., the second) that the Life membership buys you. Which means that if Whoop ends up having to pull it, you’re essentially paying an extra $120 each year for the ability to take ECG readings—a pretty standard feature on smartwatches these days. Heck, you can buy an entire Apple Watch SE for $169, and it has an ECG app. (It also will last more than a year.) So if the company has to stop offering Blood Pressure Insights, the expensive subscription doesn’t make much sense. 

“Since this is one of the selling points of Life I’m hoping there’s going to be compensation if this feature will be removed, we paid for it,” said one Redditor in a reply to Whoop’s statement. So far, the feature is still available—presumably while Whoop continues to argue its side to the FDA.





Link

0
Continue Reading

Technology

Trump, big tech companies investing in Pennsylvania energy, innovation

Trump, big tech companies investing in Pennsylvania energy, innovation – CBS News Watch CBS News President Trump unveiled $90 billion in investments in Pennsylvania energy and innovation on Tuesday. That follows Amazon’s recent announcement that it plans to invest $20 billion in data centers across the state. CBS News senior White House correspondent Weijia Jiang […]

Published

2 hours ago

on

July 16, 2025

By




Trump, big tech companies investing in Pennsylvania energy, innovation – CBS News








































Watch CBS News


President Trump unveiled $90 billion in investments in Pennsylvania energy and innovation on Tuesday. That follows Amazon’s recent announcement that it plans to invest $20 billion in data centers across the state. CBS News senior White House correspondent Weijia Jiang reports.

Be the first to know

Get browser notifications for breaking news, live events, and exclusive reporting.




Link

0
Continue Reading

Technology

AI Breakthrough: Mental Health Detection Through Selfie Video Technology

Medical Care Technologies (OTC PINK:MDCE) has unveiled an AI-powered Facial Micro-Expression Mental Health Scanner that can detect early signs of emotional and psychological distress through short selfie videos. The technology combines facial coding with affective computing to identify subtle emotional biomarkers that may indicate conditions like depression, […]

Published

3 hours ago

on

July 16, 2025

By









Medical Care Technologies (OTC PINK:MDCE) has unveiled an AI-powered Facial Micro-Expression Mental Health Scanner that can detect early signs of emotional and psychological distress through short selfie videos. The technology combines facial coding with affective computing to identify subtle emotional biomarkers that may indicate conditions like depression, anxiety, or PTSD before visible symptoms appear.

The innovation targets the global mental health tech market, projected to exceed $60 billion by 2030. The company plans to integrate this technology across multiple platforms including telehealth, university counseling centers, and wearable devices, aiming to provide scalable, stigma-free mental health screening solutions.

Medical Care Technologies (OTC PINK:MDCE) ha presentato uno scanner mentale per micro-espressioni facciali basato su intelligenza artificiale, in grado di rilevare precocemente segnali di disagio emotivo e psicologico attraverso brevi video selfie. La tecnologia combina il riconoscimento facciale con il calcolo affettivo per individuare sottili biomarcatori emotivi che potrebbero indicare condizioni come depressione, ansia o PTSD prima che compaiano sintomi visibili.

L’innovazione si rivolge al mercato globale della tecnologia per la salute mentale, previsto superare i 60 miliardi di dollari entro il 2030. L’azienda intende integrare questa tecnologia su più piattaforme, tra cui telemedicina, centri di consulenza universitaria e dispositivi indossabili, con l’obiettivo di offrire soluzioni di screening mentale scalabili e senza stigma.

Medical Care Technologies (OTC PINK:MDCE) ha presentado un escáner de salud mental basado en IA que analiza microexpresiones faciales y puede detectar signos tempranos de angustia emocional y psicológica a través de videos cortos tipo selfie. La tecnología combina codificación facial con computación afectiva para identificar biomarcadores emocionales sutiles que podrían indicar condiciones como depresión, ansiedad o TEPT antes de que aparezcan síntomas visibles.

La innovación está dirigida al mercado global de tecnología para la salud mental, que se proyecta superar los 60 mil millones de dólares para 2030. La compañía planea integrar esta tecnología en múltiples plataformas, incluyendo telemedicina, centros de consejería universitaria y dispositivos wearables, con el objetivo de ofrecer soluciones de detección mental escalables y libres de estigma.

Medical Care Technologies (OTC PINK:MDCE)는 짧은 셀카 영상으로 초기 감정 및 심리적 고통 신호를 감지할 수 있는 AI 기반 얼굴 미세표정 정신건강 스캐너를 공개했습니다. 이 기술은 얼굴 인식과 감성 컴퓨팅을 결합하여 우울증, 불안, PTSD와 같은 상태를 나타낼 수 있는 미묘한 감정 생체표지를 증상이 나타나기 전에 식별합니다.

이 혁신은 2030년까지 600억 달러를 초과할 것으로 예상되는 전 세계 정신건강 기술 시장을 목표로 합니다. 회사는 이 기술을 원격진료, 대학 상담 센터, 웨어러블 기기 등 다양한 플랫폼에 통합하여 확장 가능하고 낙인 없는 정신건강 검사 솔루션을 제공할 계획입니다.

Medical Care Technologies (OTC PINK:MDCE) a dévoilé un scanner de santé mentale basé sur l’IA capable de détecter précocement les signes de détresse émotionnelle et psychologique à partir de courtes vidéos selfie. Cette technologie combine le codage facial et l’informatique affective pour identifier des biomarqueurs émotionnels subtils pouvant indiquer des troubles comme la dépression, l’anxiété ou le PTSD avant l’apparition de symptômes visibles.

L’innovation vise le marché mondial des technologies de la santé mentale, dont la valeur devrait dépasser 60 milliards de dollars d’ici 2030. L’entreprise prévoit d’intégrer cette technologie sur plusieurs plateformes, notamment la télésanté, les centres de conseil universitaires et les dispositifs portables, afin de proposer des solutions de dépistage mental évolutives et sans stigmatisation.

Medical Care Technologies (OTC PINK:MDCE) hat einen KI-gestützten Scanner für mikro-faciale Ausdrucksweisen zur mentalen Gesundheit vorgestellt, der frühe Anzeichen emotionaler und psychologischer Belastungen durch kurze Selfie-Videos erkennen kann. Die Technologie kombiniert Gesichtscodierung mit affektiver Datenverarbeitung, um subtile emotionale Biomarker zu identifizieren, die auf Zustände wie Depression, Angststörungen oder PTBS hinweisen können, bevor sichtbare Symptome auftreten.

Die Innovation richtet sich an den globalen Markt für Mental-Health-Technologie, der bis 2030 voraussichtlich 60 Milliarden Dollar übersteigen wird. Das Unternehmen plant, diese Technologie in verschiedenen Plattformen wie Telemedizin, universitären Beratungsstellen und Wearables zu integrieren, mit dem Ziel skalierbarer, stigmatisierungsfreier Mental-Health-Screening-Lösungen.

Positive


  • Innovation in AI-powered mental health screening technology targeting a $60B market by 2030


  • Non-invasive, scalable solution accessible through smartphones and connected devices


  • Multiple integration pathways across telehealth, education, and consumer platforms


  • Potential for early detection and improved mental health outcomes


Negative


  • Early-stage technology without proven clinical validation


  • Operating in highly competitive AI healthcare space


  • No mention of regulatory approvals or clinical trials


  • Potential privacy concerns with facial recognition technology













AI-Powered Emotion Scanner Aims to Revolutionize Mental Health Screening Across Telehealth, Education & Consumer Platforms

MESA, ARIZONA / ACCESS Newswire / July 15, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a health-tech innovator pushing the boundaries of AI-powered diagnostics, today announces a major advancement in its digital health portfolio: an AI Facial Micro-Expression Mental Health Scanner designed to detect early emotional and psychological distress using nothing more than a short selfie video.

This next-gen technology merges facial coding with affective computing, decoding subtle micro-expressions that often precede visible symptoms of depression, anxiety, or PTSD. By identifying these emotional biomarkers before patients even recognize the signs themselves, MDCE is laying the groundwork for real-time, scalable, preventive mental health screening.

“This technology has the potential to redefine how mental health is approached globally,” said a company spokesperson. “With integration pathways ranging from telehealth to university counseling centers to wearable platforms, we are targeting a market that is not only underserved, but urgently in need of scalable, stigma-free solutions.”

The global mental health tech market is projected to exceed $60 billion by 2030, and MDCE’s innovation is positioned at the intersection of artificial intelligence, digital therapeutics, and mass accessibility. By enabling frictionless, non-invasive screening via smartphones and connected devices, the company believes this solution could transform both early detection and long-term outcomes for millions worldwide.

This initiative is part of MDCE’s expanding R&D focus, alongside its subsidiaries:

To learn more about the scanner or opportunities for early-stage collaboration, visit www.medicalcaretechnologies.com.

About Medical Care Technologies Inc. (OTC Pink: MDCE)

Medical Care Technologies Inc. is a forward-focused health tech company developing AI-based self-screening tools to empower users through early detection. With growing interest in AI diagnostic platforms, MDCE is developing solutions for wound care, dermatological monitoring, and mental health, targeting large and underserved markets.

Safe Harbor Statement

This press release contains forward-looking statements, including expectations for future product development and market impact. These statements involve risks and uncertainties. Actual results may differ. The company assumes no obligation to update these statements.

Company Info:
Medical Care Technologies Inc (OTC PINK:MDCE)
www.medicalcaretechnologies.com

Investor & Media Contact:
Infinite Auctions / MDCE
info@infiniteauctions.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire









FAQ



What is MDCE’s new AI mental health technology?


MDCE has developed an AI Facial Micro-Expression Mental Health Scanner that can detect early signs of emotional and psychological distress by analyzing short selfie videos, identifying subtle micro-expressions that may indicate conditions like depression, anxiety, or PTSD.


How does MDCE’s AI mental health scanner work?


The technology uses facial coding and affective computing to analyze micro-expressions in selfie videos, detecting emotional biomarkers that may indicate mental health conditions before visible symptoms appear.


What is the market potential for MDCE’s mental health technology?


The global mental health tech market is projected to exceed $60 billion by 2030, with MDCE’s technology targeting multiple integration pathways including telehealth, university counseling centers, and wearable platforms.


Where will MDCE’s mental health scanning technology be implemented?


The technology is planned for integration across multiple platforms including telehealth services, university counseling centers, and wearable devices, aiming to provide widespread, accessible mental health screening.


What are MDCE’s subsidiary companies?


MDCE operates two subsidiaries: Infinite Auctions, specializing in investment-grade memorabilia auctions, and Real Game Used, focusing on AI photo-match authentication and sports-tech solutions.








Link

5
Continue Reading

Technology

Catapult Group Announces Director’s Interest Change

Elevate Your Investing Strategy: Catapult Group International ( (AU:CAT) ) just unveiled an update. Catapult Group International Ltd has announced a change in the director’s interest notice, involving Mr. James Ventura Orlando. The change includes the conversion of FY25 Director Fee Sacrifice Rights into fully paid ordinary shares and the acquisition of FY26 Director Fee […]

Published

3 hours ago

on

July 16, 2025

By


Elevate Your Investing Strategy:

Catapult Group International ( (AU:CAT) ) just unveiled an update.

Catapult Group International Ltd has announced a change in the director’s interest notice, involving Mr. James Ventura Orlando. The change includes the conversion of FY25 Director Fee Sacrifice Rights into fully paid ordinary shares and the acquisition of FY26 Director Fee Sacrifice Rights. This adjustment reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting the company’s governance and stakeholder relations.

The most recent analyst rating on (AU:CAT) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Catapult Group International stock, see the AU:CAT Stock Forecast page.

More about Catapult Group International

Catapult Group International Ltd operates in the sports technology industry, providing performance analytics and wearable technology solutions primarily for sports teams and athletes. The company focuses on enhancing athletic performance and optimizing team management through data-driven insights.

Average Trading Volume: 1,379,572

Technical Sentiment Signal: Buy

Current Market Cap: A$1.61B

For an in-depth examination of CAT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue



Link

0
Continue Reading

Technology

OTC PINK:MDCE – Medical Care Technologies Unveils Game-Changing AI Mental Health Breakthrough

PRESS RELEASE Published July 15, 2025 AI-Powered Emotion Scanner Aims to Revolutionize Mental Health Screening Across Telehealth, Education & Consumer Platforms MESA, ARIZONA / ACCESS Newswire / July 15, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a health-tech innovator pushing the boundaries of AI-powered diagnostics, today announces a major advancement in its digital health […]

Published

4 hours ago

on

July 15, 2025

By


PRESS RELEASE

Published July 15, 2025

AI-Powered Emotion Scanner Aims to Revolutionize Mental Health Screening Across Telehealth, Education & Consumer Platforms

MESA, ARIZONA / ACCESS Newswire / July 15, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a health-tech innovator pushing the boundaries of AI-powered diagnostics, today announces a major advancement in its digital health portfolio: an AI Facial Micro-Expression Mental Health Scanner designed to detect early emotional and psychological distress using nothing more than a short selfie video.

This next-gen technology merges facial coding with affective computing, decoding subtle micro-expressions that often precede visible symptoms of depression, anxiety, or PTSD. By identifying these emotional biomarkers before patients even recognize the signs themselves, MDCE is laying the groundwork for real-time, scalable, preventive mental health screening.

“This technology has the potential to redefine how mental health is approached globally,” said a company spokesperson. “With integration pathways ranging from telehealth to university counseling centers to wearable platforms, we are targeting a market that is not only underserved, but urgently in need of scalable, stigma-free solutions.”

The global mental health tech market is projected to exceed $60 billion by 2030, and MDCE’s innovation is positioned at the intersection of artificial intelligence, digital therapeutics, and mass accessibility. By enabling frictionless, non-invasive screening via smartphones and connected devices, the company believes this solution could transform both early detection and long-term outcomes for millions worldwide.

This initiative is part of MDCE’s expanding R&D focus, alongside its subsidiaries:

To learn more about the scanner or opportunities for early-stage collaboration, visit www.medicalcaretechnologies.com.

About Medical Care Technologies Inc. (OTC Pink: MDCE)

Medical Care Technologies Inc. is a forward-focused health tech company developing AI-based self-screening tools to empower users through early detection. With growing interest in AI diagnostic platforms, MDCE is developing solutions for wound care, dermatological monitoring, and mental health, targeting large and underserved markets.

Safe Harbor Statement

This press release contains forward-looking statements, including expectations for future product development and market impact. These statements involve risks and uncertainties. Actual results may differ. The company assumes no obligation to update these statements.

Company Info:
Medical Care Technologies Inc (OTC PINK:MDCE)
www.medicalcaretechnologies.com

Investor & Media Contact:
Infinite Auctions / MDCE
info@infiniteauctions.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

ACCESS Newswire

ACCESS Newswire is a newswire service that provides regional, national, and global news to thousands of clients worldwide. Its innovative technology paired with its expansive network of journalists and media outlets helps companies, both public and private, break through the noise of the market to share their stories and connect with their audiences.



Link

0
Continue Reading

Most Viewed Posts

Trending